281 related articles for article (PubMed ID: 15661147)
1. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.
Pancera M; Wyatt R
Virology; 2005 Feb; 332(1):145-56. PubMed ID: 15661147
[TBL] [Abstract][Full Text] [Related]
2. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
3. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.
Grundner C; Mirzabekov T; Sodroski J; Wyatt R
J Virol; 2002 Apr; 76(7):3511-21. PubMed ID: 11884575
[TBL] [Abstract][Full Text] [Related]
4. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
[TBL] [Abstract][Full Text] [Related]
5. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
7. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
8. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F
Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888
[TBL] [Abstract][Full Text] [Related]
9. The HIV-1 Env protein signal sequence retards its cleavage and down-regulates the glycoprotein folding.
Li Y; Luo L; Thomas DY; Kang CY
Virology; 2000 Jul; 272(2):417-28. PubMed ID: 10873786
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
Grundner C; Li Y; Louder M; Mascola J; Yang X; Sodroski J; Wyatt R
Virology; 2005 Jan; 331(1):33-46. PubMed ID: 15582651
[TBL] [Abstract][Full Text] [Related]
11. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
VanCott TC; Kaminski RW; Mascola JR; Kalyanaraman VS; Wassef NM; Alving CR; Ulrich JT; Lowell GH; Birx DL
J Immunol; 1998 Feb; 160(4):2000-12. PubMed ID: 9469464
[TBL] [Abstract][Full Text] [Related]
13. Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation.
Zhang Z; Wang Q; Nguyen HT; Chen HC; Chiu TJ; Smith Iii AB; Sodroski JG
J Virol; 2023 Sep; 97(9):e0059223. PubMed ID: 37696048
[TBL] [Abstract][Full Text] [Related]
14. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
[TBL] [Abstract][Full Text] [Related]
15. Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.
Herrera C; Klasse PJ; Kibler CW; Michael E; Moore JP; Beddows S
Virology; 2006 Jul; 351(1):121-32. PubMed ID: 16616288
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
17. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
[TBL] [Abstract][Full Text] [Related]
18. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
VanCott TC; Mascola JR; Kaminski RW; Kalyanaraman V; Hallberg PL; Burnett PR; Ulrich JT; Rechtman DJ; Birx DL
J Virol; 1997 Jun; 71(6):4319-30. PubMed ID: 9151820
[TBL] [Abstract][Full Text] [Related]
19. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.
Dey AK; David KB; Klasse PJ; Moore JP
Virology; 2007 Mar; 360(1):199-208. PubMed ID: 17092531
[TBL] [Abstract][Full Text] [Related]
20. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins.
Grundner C; Pancera M; Kang JM; Koch M; Sodroski J; Wyatt R
Virology; 2004 Dec; 330(1):233-48. PubMed ID: 15527849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
